Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 3/20 | 0.31 |
| ▸ | GSK3B | P49841 | 3/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | CLK3 | P49761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364365 | 0.90 | MAP3K5 (0.36) | TAS2R8MAP3K5 | |
| SCHEMBL20162127 | 0.88 | TAS2R8 (0.47) | TAS2R8WNT1GSK3BDYRK1AMAP3K5 | |
| SCHEMBL20169969 | 0.78 | ESR2 (0.46) | TAS2R8WNT1GSK3BDYRK1AMAP3K5 | |
| SCHEMBL20162154 | 0.76 | MAP3K5 (0.37) | MAP3K5 | |
| SCHEMBL20364368 | 0.75 | MAP3K5 (0.40) | TAS2R8MAP3K5 | |
| SCHEMBL20162123 | 0.71 | WNT1 (0.35) | WNT1GSK3BDYRK1ACLK2CLK3 | |
| SCHEMBL19304330 | 0.71 | KMT2A (0.49) | — | |
| SCHEMBL14858625 | 0.71 | MAP3K5 (0.37) | MAP3K5RIPK1 | |
| SCHEMBL20364335 | 0.70 | MAP3K5 (0.38) | TAS2R8MAP3K5RIPK1 | |
| SCHEMBL20364366 | 0.70 | MAPT (0.41) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885WNT1 223/4885GSK3B 3570/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885WNT1 223/4885GSK3B 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.